New vaccines needed for pathogens infecting animals and humans

References

• OIE. Hendra and Nipah viruses diseases. Manual of diagnostic tests and vaccines for terrestrial animals. 2010:Chapter 2.9.6.
   Google Scholar
• Greger M. The human/animal interface: emergence and resurgence of zoonotic infectious diseases. Crit Rev Microbiol 2007; 33:243 - 99; http://dx.doi.org/10.1080/10408410701647594; PMID: 18033595
   PubMed Web of Science ®Google Scholar
• Sims LD, Domenech J, Benigno C, Kahn S, Kamata A, Lubroth J, et al. Origin and evolution of highly pathogenic H5N1 avian influenza in Asia. Vet Rec 2005; 157:159 - 64; PMID: 16085721
   PubMed Web of Science ®Google Scholar
• Capua I, Alexander DJ. Avian influenza infection in birds: a challenge and opportunity for the poultry veterinarian. Poult Sci 2009; 88:842 - 6; http://dx.doi.org/10.3382/ps.2008-00289; PMID: 19276432
   PubMed Web of Science ®Google Scholar
• Suarez DL. Avian influenza: our current understanding. Anim Health Res Rev 2010; 11:19 - 33; http://dx.doi.org/10.1017/S1466252310000095; PMID: 20591211
   PubMedGoogle Scholar
• Oner AF, Bay A, Arslan S, Akdeniz H, Sahin HA, Cesur Y, et al. Avian influenza A (H5N1) infection in eastern Turkey in 2006. N Engl J Med 2006; 355:2179 - 85; http://dx.doi.org/10.1056/NEJMoa060601; PMID: 17124015
   PubMed Web of Science ®Google Scholar
• Chmielewski R, Swayne DE. Avian influenza: public health and food safety concerns. Annu Rev Food Sci Technol 2011; 2:37 - 57; PMID: 22129374
   PubMed Web of Science ®Google Scholar
• WHO. H5N1 avian influenza: Timeline of major events. 13 December 2011. Retrieved from http://www.who.int/influenza/human_animal_interface/avian_influenza/H5N1_avian_influenza_update.pdf. Accessed: 1/28/2012.
   Google Scholar
• Octaviani CP, Ozawa M, Yamada S, Goto H, Kawaoka Y. High level of genetic compatibility between swine-origin H1N1 and highly pathogenic avian H5N1 influenza viruses. J Virol 2010; 84:10918 - 22; http://dx.doi.org/10.1128/JVI.01140-10; PMID: 20686037
   PubMed Web of Science ®Google Scholar
• WHO/GIP. Cumulative number of confirmed human cases for avian influenza A(H5N1) reported to WHO, 2003–2012. Retrieved from http://www.who.int/influenza/human_animal_interface/ EN_GIP_20120124CumulativeNumberH5N1cases.pdf. Accessed: 1/14/2012.
   Google Scholar
• WHO/GAR. Avian influenza – situation in Indonesia – update, 12 March 2012. Retrieved from http://www.who.int/csr/don/2012_03_12b/en/index.html. Accessed: 3/15/2012.
   Google Scholar
• Wang L, Harcourt BH, Yu M, Tamin A, Rota PA, Bellini WJ, et al. Molecular biology of Hendra and Nipah viruses. Microbes Infect 2001; 3:279 - 87; http://dx.doi.org/10.1016/S1286-4579(01)01381-8; PMID: 11334745
   PubMed Web of Science ®Google Scholar
• Young PL, Halpin K, Selleck PW, Field H, Gravel JL, Kelly MA, et al. Serologic evidence for the presence in Pteropus bats of a paramyxovirus related to equine morbillivirus. Emerg Infect Dis 1996; 2:239 - 40; http://dx.doi.org/10.3201/eid0203.960315; PMID: 8903239
   PubMed Web of Science ®Google Scholar
• Chua KB. Nipah virus outbreak in Malaysia. J Clin Virol 2003; 26:265 - 75; http://dx.doi.org/10.1016/S1386-6532(02)00268-8; PMID: 12637075
   PubMed Web of Science ®Google Scholar
• Bossart KN, Crameri G, Dimitrov AS, Mungall BA, Feng YR, Patch JR, et al. Receptor binding, fusion inhibition, and induction of cross-reactive neutralizing antibodies by a soluble G glycoprotein of Hendra virus. J Virol 2005; 79:6690 - 702; http://dx.doi.org/10.1128/JVI.79.11.6690-6702.2005; PMID: 15890907
   PubMed Web of Science ®Google Scholar
• Mohd Nor MN, Gan CH, Ong BL. Nipah virus infection of pigs in peninsular Malaysia. Rev Sci Tech 2000; 19:160 - 5; PMID: 11189713
   PubMed Web of Science ®Google Scholar
• Murray K, Selleck P, Hooper P, Hyatt A, Gould A, Gleeson L, et al. A morbillivirus that caused fatal disease in horses and humans. Science 1995; 268:94 - 7; http://dx.doi.org/10.1126/science.7701348; PMID: 7701348
   PubMed Web of Science ®Google Scholar
• Field H, Schaaf K, Kung N, Simon C, Waltisbuhl D, Hobert H, et al. Hendra virus outbreak with novel clinical features, Australia. Emerg Infect Dis 2010; 16:338 - 40; PMID: 20113576
   PubMed Web of Science ®Google Scholar
• Playford EG, McCall B, Smith G, Slinko V, Allen G, Smith I, et al. Human Hendra virus encephalitis associated with equine outbreak, Australia, 2008. Emerg Infect Dis 2010; 16:219 - 23; PMID: 20113550
   PubMed Web of Science ®Google Scholar
• Field H, de Jong C, Melville D, Smith C, Smith I, Broos A, et al. Hendra virus infection dynamics in Australian fruit bats. PLoS One 2011; 6:e28678; http://dx.doi.org/10.1371/journal.pone.0028678; PMID: 22174865
   PubMed Web of Science ®Google Scholar
• Weingartl H, Czub S, Copps J, Berhane Y, Middleton D, Marszal P, et al. Invasion of the central nervous system in a porcine host by nipah virus. J Virol 2005; 79:7528 - 34; http://dx.doi.org/10.1128/JVI.79.12.7528-7534.2005; PMID: 15919907
   PubMed Web of Science ®Google Scholar
• van Oirschot JT. Present and future of veterinary viral vaccinology: a review. Vet Q 2001; 23:100 - 8; http://dx.doi.org/10.1080/01652176.2001.9695094; PMID: 11513250
   PubMed Web of Science ®Google Scholar
• Weingartl HM, Berhane Y, Caswell JL, Loosmore S, Audonnet JC, Roth JA, et al. Recombinant nipah virus vaccines protect pigs against challenge. J Virol 2006; 80:7929 - 38; http://dx.doi.org/10.1128/JVI.00263-06; PMID: 16873250
   PubMed Web of Science ®Google Scholar
• Guillaume V, Contamin H, Loth P, Georges-Courbot MC, Lefeuvre A, Marianneau P, et al. Nipah virus: vaccination and passive protection studies in a hamster model. J Virol 2004; 78:834 - 40; http://dx.doi.org/10.1128/JVI.78.2.834-840.2004; PMID: 14694115
   PubMed Web of Science ®Google Scholar
• Mungall BA, Middleton D, Crameri G, Bingham J, Halpin K, Russell G, et al. Feline model of acute nipah virus infection and protection with a soluble glycoprotein-based subunit vaccine. J Virol 2006; 80:12293 - 302; http://dx.doi.org/10.1128/JVI.01619-06; PMID: 17005664
   PubMed Web of Science ®Google Scholar
• Hassan OA, Ahlm C, Sang R, Evander M. The 2007 Rift Valley fever outbreak in Sudan. PLoS Negl Trop Dis 2011; 5:e1229; http://dx.doi.org/10.1371/journal.pntd.0001229; PMID: 21980543
   PubMed Web of Science ®Google Scholar
• McIntosh BM, Russell D, dos Santos I, Gear JH. Rift Valley fever in humans in South Africa. S Afr Med J 1980; 58:803 - 6; PMID: 7192434
   PubMed Web of Science ®Google Scholar
• Bird BH, Albariño CG, Hartman AL, Erickson BR, Ksiazek TG, Nichol ST. Rift valley fever virus lacking the NSs and NSm genes is highly attenuated, confers protective immunity from virulent virus challenge, and allows for differential identification of infected and vaccinated animals. J Virol 2008; 82:2681 - 91; http://dx.doi.org/10.1128/JVI.02501-07; PMID: 18199647
   PubMed Web of Science ®Google Scholar
• Madani TA, Al-Mazrou YY, Al-Jeffri MH, Mishkhas AA, Al-Rabeah AM, Turkistani AM, et al. Rift Valley fever epidemic in Saudi Arabia: epidemiological, clinical, and laboratory characteristics. Clin Infect Dis 2003; 37:1084 - 92; http://dx.doi.org/10.1086/378747; PMID: 14523773
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention (CDC). Rift Valley fever outbreak--Kenya, November 2006-January 2007. MMWR Morb Mortal Wkly Rep 2007; 56:73 - 6; PMID: 17268404
   PubMedGoogle Scholar
• Meadors GF 3rd, Gibbs PH, Peters CJ. Evaluation of a new Rift Valley fever vaccine: safety and immunogenicity trials. Vaccine 1986; 4:179 - 84; http://dx.doi.org/10.1016/0264-410X(86)90007-1; PMID: 3532605
   PubMed Web of Science ®Google Scholar
• Randall R, Binn LN, Harrison VR. Immunization against Rift Valley Fever Virus. Studies on the Immunogenicity of Lyophilized Formalin-Inactivated Vaccine. J Immunol 1964; 93:293 - 9; PMID: 14202259
   PubMed Web of Science ®Google Scholar
• Gerdes GH. Rift valley fever. Vet Clin North Am Food Anim Pract 2002; 18:549 - 55; http://dx.doi.org/10.1016/S0749-0720(02)00029-4; PMID: 12442582
   PubMed Web of Science ®Google Scholar
• Caplen H, Peters CJ, Bishop DH. Mutagen-directed attenuation of Rift Valley fever virus as a method for vaccine development. J Gen Virol 1985; 66:2271 - 7; http://dx.doi.org/10.1099/0022-1317-66-10-2271; PMID: 4045430
   PubMed Web of Science ®Google Scholar
• Morrill JC, Carpenter L, Taylor D, Ramsburg HH, Quance J, Peters CJ. Further evaluation of a mutagen-attenuated Rift Valley fever vaccine in sheep. Vaccine 1991; 9:35 - 41; http://dx.doi.org/10.1016/0264-410X(91)90314-V; PMID: 2008798
   PubMed Web of Science ®Google Scholar
• Morrill JC, Mebus CA, Peters CJ. Safety of a mutagen-attenuated Rift Valley fever virus vaccine in fetal and neonatal bovids. Am J Vet Res 1997; 58:1110 - 4; PMID: 9328663
   PubMed Web of Science ®Google Scholar
• Morrill JC, Peters CJ. Pathogenicity and neurovirulence of a mutagen-attenuated Rift Valley fever vaccine in rhesus monkeys. Vaccine 2003; 21:2994 - 3002; http://dx.doi.org/10.1016/S0264-410X(03)00131-2; PMID: 12798643
   PubMed Web of Science ®Google Scholar
• Muller R, Saluzzo JF, Lopez N, Dreier T, Turell M, Smith J, et al. Characterization of clone 13, a naturally attenuated avirulent isolate of Rift Valley fever virus, which is altered in the small segment. Am J Trop Med Hyg 1995; 53:405 - 11; PMID: 7485695
   PubMed Web of Science ®Google Scholar
• Dungu B, Louw I, Lubisi A, Hunter P, von Teichman BF, Bouloy M. Evaluation of the efficacy and safety of the Rift Valley Fever Clone 13 vaccine in sheep. Vaccine 2010; 28:4581 - 7; http://dx.doi.org/10.1016/j.vaccine.2010.04.085; PMID: 20470792
   PubMed Web of Science ®Google Scholar
• Domingo E, Baranowski E, Escarmís C, Sobrino F. Foot-and-mouth disease virus. Comp Immunol Microbiol Infect Dis 2002; 25:297 - 308; http://dx.doi.org/10.1016/S0147-9571(02)00027-9; PMID: 12365806
   PubMed Web of Science ®Google Scholar
• Grubman MJ, Baxt B. Foot-and-mouth disease. Clin Microbiol Rev 2004; 17:465 - 93; http://dx.doi.org/10.1128/CMR.17.2.465-493.2004; PMID: 15084510
   PubMed Web of Science ®Google Scholar
• Rodriguez LL, Gay CG. Development of vaccines toward the global control and eradication of foot-and-mouth disease. Expert Rev Vaccines 2011; 10:377 - 87; http://dx.doi.org/10.1586/erv.11.4; PMID: 21434805
   PubMed Web of Science ®Google Scholar
• Forman S, Le Gall F, Belton D, Evans B, François JL, Murray G, et al. Moving towards the global control of foot and mouth disease: an opportunity for donors. Rev Sci Tech 2009; 28:883 - 96; PMID: 20462147
   PubMed Web of Science ®Google Scholar
• De Clercq K, Goris N, Barnett PV, MacKay DK. The importance of quality assurance/quality control of diagnostics to increase the confidence in global foot-and-mouth disease control. Transbound Emerg Dis 2008; 55:35 - 45; http://dx.doi.org/10.1111/j.1865-1682.2007.01011.x; PMID: 18397507
   PubMed Web of Science ®Google Scholar
• Cubillos C, de la Torre BG, Jakab A, Clementi G, Borrás E, Bárcena J, et al. Enhanced mucosal immunoglobulin A response and solid protection against foot-and-mouth disease virus challenge induced by a novel dendrimeric peptide. J Virol 2008; 82:7223 - 30; http://dx.doi.org/10.1128/JVI.00401-08; PMID: 18448530
   PubMed Web of Science ®Google Scholar
• Pacheco JM, Brum MC, Moraes MP, Golde WT, Grubman MJ. Rapid protection of cattle from direct challenge with foot-and-mouth disease virus (FMDV) by a single inoculation with an adenovirus-vectored FMDV subunit vaccine. Virology 2005; 337:205 - 9; http://dx.doi.org/10.1016/j.virol.2005.04.014; PMID: 15893355
   PubMed Web of Science ®Google Scholar
• Grubman MJ, Moraes MP, Schutta C, Barreda J, Neilan J, Ettyreddy D, et al. Adenovirus serotype 5-vectored foot-and- mouth disease subunit vaccines: the first decade. Future Virol. 2010; 5:51 - 64; http://dx.doi.org/10.2217/fvl.09.68
   Web of Science ®Google Scholar
• US Census Bureau. International Database. Retrieved from http://www.census.gov/population/ international/data/idb/worldpoptotal.php. Accessed: 1/10/2012.
   Google Scholar
• Chen LM, Blixt O, Stevens J, Lipatov AS, Davis CT, Collins BE, et al. In vitro evolution of H5N1 avian influenza virus toward human-type receptor specificity. Virology 2012; 422:105 - 13; http://dx.doi.org/10.1016/j.virol.2011.10.006; PMID: 22056389
   PubMed Web of Science ®Google Scholar
• Zinsstag J. Animal health research. Science 2007; 315:1193; http://dx.doi.org/10.1126/science.1141278; PMID: 17332379
   PubMed Web of Science ®Google Scholar
• Grobbelaar AA, Weyer J, Leman PA, Kemp A, Paweska JT, Swanepoel R. Molecular epidemiology of Rift Valley fever virus. Emerg Infect Dis 2011; 17:2270 - 6; http://dx.doi.org/10.3201/eid1712.111035; PMID: 22172568
   PubMed Web of Science ®Google Scholar
• FAO. Rift Valley fever vaccine development, progress and constraints. Proceedings of the GF-TADs meeting, November 2010, Rome, Italy. FAO Animal Production and Health Proceedings, 2011; No. 12. Rome, Italy.
   Google Scholar
• Taylor LH, Latham SM, Woolhouse ME. Risk factors for human disease emergence. Philos Trans R Soc Lond B Biol Sci 2001; 356:983 - 9; http://dx.doi.org/10.1098/rstb.2001.0888; PMID: 11516376
   PubMed Web of Science ®Google Scholar
• De Groot AS, Bosma A, Chinai N, Frost J, Jesdale BM, Gonzalez MA, et al. From genome to vaccine: in silico predictions, ex vivo verification. Vaccine 2001; 19:4385 - 95; http://dx.doi.org/10.1016/S0264-410X(01)00145-1; PMID: 11483263
   PubMed Web of Science ®Google Scholar
• Zhang Q, Wang P, Kim Y, Haste-Andersen P, Beaver J, Bourne PE, et al. Immune epitope database analysis resource (IEDB-AR). Nucleic Acids Res 2008; 36:Web Server issue W513-8; http://dx.doi.org/10.1093/nar/gkn254; PMID: 18515843
   PubMedGoogle Scholar
• Schafer JR, Jesdale BM, George JA, Kouttab NM, De Groot AS. Prediction of well-conserved HIV-1 ligands using a matrix-based algorithm, EpiMatrix. Vaccine 1998; 16:1880 - 4; http://dx.doi.org/10.1016/S0264-410X(98)00173-X; PMID: 9795396
   PubMed Web of Science ®Google Scholar
• Moise L, McMurry JA, Pappo J, Lee DS, Moss SF, Martin WD, et al. Identification of genome-derived vaccine candidates conserved between human and mouse-adapted strains of H. pylori. Hum Vaccin 2008; 4:219 - 23; http://dx.doi.org/10.4161/hv.4.3.5394; PMID: 18376134
   PubMed Web of Science ®Google Scholar
• De Groot AS, Marcon L, Bishop EA, Rivera D, Kutzler M, Weiner DB, et al. HIV vaccine development by computer assisted design: the GAIA vaccine. Vaccine 2005; 23:2136 - 48; http://dx.doi.org/10.1016/j.vaccine.2005.01.097; PMID: 15755584
   PubMed Web of Science ®Google Scholar
• Schanen BC, De Groot AS, Moise L, Ardito M, McClaine E, Martin W, et al. Coupling sensitive in vitro and in silico techniques to assess cross-reactive CD4(+) T cells against the swine-origin H1N1 influenza virus. Vaccine 2011; 29:3299 - 309; http://dx.doi.org/10.1016/j.vaccine.2011.02.019; PMID: 21349362
   PubMed Web of Science ®Google Scholar
• De Groot AS, Ardito MA, Tassone R, Knopf P. Moise L, and Martin W. Tools for Vaccine Design: Prediction and Validation of Highly Immunogenic and Conserved Class II Epitopes and Development of Epitope-driven Vaccines. In: Srivastava I. and M. Singh, eds. Development of Vaccines: From Discovery to Clinical Testing. New Jersey: John Wiley and Sons, 2011.
   Google Scholar
• Sturniolo T, Bono E, Ding J, Raddrizzani L, Tuereci O, Sahin U, et al. Generation of tissue-specific and promiscuous HLA ligand databases using DNA microarrays and virtual HLA class II matrices. Nat Biotechnol 1999; 17:555 - 61; http://dx.doi.org/10.1038/9858; PMID: 10385319
   PubMed Web of Science ®Google Scholar
• De Groot AS, Nene V, Hegde NR, Srikumaran S, Rayner J, Martin W. T cell epitope identification for bovine vaccines: an epitope mapping method for BoLA A-11. Int J Parasitol 2003; 33:641 - 53; http://dx.doi.org/10.1016/S0020-7519(03)00051-1; PMID: 12782061
   PubMed Web of Science ®Google Scholar
• Pedersen LE, Harndahl M, Rasmussen M, Lamberth K, Golde WT, Lund O, et al. Porcine major histocompatibility complex (MHC) class I molecules and analysis of their peptide-binding specificities. Immunogenetics 2011; 63:821 - 34; http://dx.doi.org/10.1007/s00251-011-0555-3; PMID: 21739336
   PubMed Web of Science ®Google Scholar
• Blignaut B, Visser N, Theron J, Rieder E, Maree FF. Custom-engineered chimeric foot-and-mouth disease vaccine elicits protective immune responses in pigs. J Gen Virol 2011; 92:849 - 59; http://dx.doi.org/10.1099/vir.0.027151-0; PMID: 21177923
   PubMed Web of Science ®Google Scholar
• Adams LG, Khare S, Lawhon SD, Rossetti CA, Lewin HA, Lipton MS, et al. Enhancing the role of veterinary vaccines reducing zoonotic diseases of humans: linking systems biology with vaccine development. Vaccine 2011; 29:7197 - 206; http://dx.doi.org/10.1016/j.vaccine.2011.05.080; PMID: 21651944
   PubMed Web of Science ®Google Scholar
• McNeela EA, Lavelle EC. Recent advances in microparticle and nanoparticle delivery vehicles for mucosal vaccination. Curr Top Microbiol Immunol 2012; 354:75 - 99; http://dx.doi.org/10.1007/82_2011_140; PMID: 21904984
   PubMed Web of Science ®Google Scholar
• Moss SF, Moise L, Lee DS, Kim W, Zhang S, Lee J, et al. HelicoVax: epitope-based therapeutic Helicobacter pylori vaccination in a mouse model. Vaccine 2011; 29:2085 - 91; http://dx.doi.org/10.1016/j.vaccine.2010.12.130; PMID: 21236233
   PubMed Web of Science ®Google Scholar
• Moise L, Buller RM, Schriewer J, Lee J, Frey SE, Weiner DB, et al. VennVax, a DNA-prime, peptide-boost multi-T-cell epitope poxvirus vaccine, induces protective immunity against vaccinia infection by T cell response alone. Vaccine 2011; 29:501 - 11; http://dx.doi.org/10.1016/j.vaccine.2010.10.064; PMID: 21055490
   PubMed Web of Science ®Google Scholar
• Shi Y, Huang G. Recent developments of biodegradable and biocompatible materials based micro/nanoparticles for delivering macromolecular therapeutics. Crit Rev Ther Drug Carrier Syst 2009; 26:29 - 84; PMID: 19496747
   PubMed Web of Science ®Google Scholar
• Scheerlinck JP, Greenwood DL. Virus-sized vaccine delivery systems. Drug Discov Today 2008; 13:882 - 7; http://dx.doi.org/10.1016/j.drudis.2008.06.016; PMID: 18656548
   PubMed Web of Science ®Google Scholar
• Trigo J, Abbehusen M, Netto EM, Nakatani M, Pedral-Sampaio G, de Jesus RS, et al. Treatment of canine visceral leishmaniasis by the vaccine Leish-111f+MPL-SE. Vaccine 2010; 28:3333 - 40; http://dx.doi.org/10.1016/j.vaccine.2010.02.089; PMID: 20206667
   PubMed Web of Science ®Google Scholar
• Schijns VE, Lavelle EC. Trends in vaccine adjuvants. Expert Rev Vaccines 2011; 10:539 - 50; http://dx.doi.org/10.1586/erv.11.21; PMID: 21506650
   PubMed Web of Science ®Google Scholar
• USDA CSRESS CRIS. FY 2010 - National Summary Tables, USDA, SAES, and other institutions. Retrived from http://cris.nifa.usda.gov/crisfin/2010/10tabled.pdf. Accessed: 3/9/2012.
   Google Scholar